RVX-297

RVX-297 is a potent, orally active BET bromodomain inhibitor with selectivity for BD2. RVX-297 shows IC50s of 0.08, 0.05, and 0.02 μM for BRD2 (BD2), BRD3 (BD2), and BRD4 (BD2), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types. RVX-297 is effective in acute inflammation and autoimmunity models[1][2].

Product Specifications

CAS Number

[1044871-04-6]

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Epigenetics

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/rvx-297.html

Purity

95.00

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1NC(C2=CC(C)=C(OCCN3CCCC3)C(C)=C2)=NC4=C1C(OC)=CC(OC)=C4

Molecular Formula

C24H29N3O4

Molecular Weight

423.50

Precautions

H302, H312, H332

References & Citations

[1]Jahagirdar R, et al. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease. Mol Pharmacol. 2017;92 (6) :694-706.|[2]Kharenko OA, et al. RVX-297- a novel BD2 selective inhibitor of BET bromodomains. Biochem Biophys Res Commun. 2016;477 (1) :62-67.